Original Article

You have full text access to this OnlineOpen article

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis

  1. Hans Carl Hasselbalch1,*,
  2. Ole Weiss Bjerrum2,
  3. Bjarne Anker Jensen3,
  4. Nielsaage Tøffner Clausen3,
  5. Per Boye Hansen3,
  6. Henrik Birgens4,
  7. Marianne Hamilton Therkildsen5,
  8. Elisabeth Ralfkiær6

Article first published online: 17 NOV 2003

DOI: 10.1002/ajh.10431

Issue

American Journal of Hematology

American Journal of Hematology

Volume 74, Issue 4, pages 238–242, December 2003

Additional Information

How to Cite

Hasselbalch, H. C., Bjerrum, O. W., Jensen, B. A., Clausen, N. T., Hansen, P. B., Birgens, H., Therkildsen, M. H. and Ralfkiær, E. (2003), Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. Am. J. Hematol., 74: 238–242. doi: 10.1002/ajh.10431

Author Information

  1. 1

    Department of Medicine, Division of Hematology and Oncology, Roskilde Hospital, Denmark

  2. 2

    Department of Hematology, Rigshospitalet, Denmark

  3. 3

    Department of Medicine F, Division of Hematology and Oncology, Hillerød Hospital, Demark

  4. 4

    Department of Hematology, Herlev Hospital, Denmark

  5. 5

    Department of Pathology, Roskilde Hospital, Denmark

  6. 6

    Department of Pathology, Rigshospitalet, Denmark

*Department of Hematology and Oncology, Roskilde Hospital, 4000 Roskilde, Denmark

Publication History

  1. Issue published online: 17 NOV 2003
  2. Article first published online: 17 NOV 2003
  3. Manuscript Accepted: 15 JUL 2003
  4. Manuscript Received: 10 DEC 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (68K)

REFERENCES

  • 1
    Ward HP, Block MH. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 1971;50:357–420.
  • 2
    Tefferi A. Myelofibrosis with myeloid metaplasia N Engl J Med 2000;342(17):1255–1265.
  • 3
    Hasselbalch HC. Idiopathic myelofibrosis. Am J Hematol 1990;34:291–300.
    Direct Link:
  • 4
    Cervantes F, Pereira A, Esteve J, et al. Identification of “short-lived” and “long-lived” patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997;97:635–640.
    Direct Link:
  • 5
    Thiele J, Zankovich R, Steinberg T, Kremer B, Fischer R, Diehl V. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis. A critical evaluation of clinical and histomorphological data. Acta Haematol 1989;81:192–202.
  • 6
    Thiele J, Kvasnicka HM, Werden C, Zankovich R, Diehl V, Fischer R. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma 1996;22:303–317.
  • 7
    Thiele J, Kvasnicka HM, Fischer R, Diehl V. Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update. Leuk Lymphoma 1997;24:463–481.
  • 8
    Castro-Malaspina H. Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. In: BerkPD, Castro-MalaspinaH, WassermanLR, editors. Myelofibrosis and the biology of connective tissue. New York: Alan R. Liss, Inc.; 1984. pp. 427–454.
  • 9
    Martyre MC, Magdelenat H, Bryckaert H, Laine-Bidron C, Calvo F. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-b in patients with myelofibrosis with myeloid, metaplasia. Br J Haematol 1991;77:80–86.
    Direct Link:
  • 10
    Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994;88:9–16.
    Direct Link:
  • 11
    Le Bousse-Kerdiles M-C, Chevillard S, Charpentier A, et al. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996;88(12):4534–4546.
  • 12
    Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997;97:441–448.
    Direct Link:
  • 13
    Le Bousse-Kerdiles MC, Martyre MC. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 1999;78:437–444.
  • 14
    Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100–104.
  • 15
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
  • 16
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038–1042.
  • 17
    Beham-Schmid C, Apfelbeck U, Sill H, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002;99:381–383.
  • 18
    Tefferi A, Mesa RA, Gray LA, et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood 2002;99:3854–3856.
  • 19
    Gisslinger H, Gisslinger B, Kees M, et al. Imatinib mesylate in chronic idiopathic myelofibrosis, a phase II trial. Blood 2002;100:800a. abstract # 3161.
  • 20
    Paggio G, Castello S, Podesta M, et al. Low number of circulating CD34+ cells identifies a group of patients with myelofibrosis with myeloid metaplasia (MMM) who efficiently responds to STI571. Blood 2001;98:Abstract # 2630.
  • 21
    Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34 (+) cells in myelofibrosis with myeloid metaplasia. Blood 2001;98(12):3249–3255.
  • 22
    Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001;97:1999–2007.
  • 23
    Canepa L, Ballerini F, Varaldo R, et al. Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol 2001;115:313–315.
    Direct Link:
  • 24
    Elliot MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002;117:288–296.
    Direct Link:
Get PDF (68K)